Y. Harutani

发表

Prospective, multicentre, single-arm phase II trial of pembrolizumab combined with carboplatin and pemetrexed in elderly patients with advanced, non-squamous non-small cell lung cancer

Takanori Yoshikawa, N. Yamamoto, Y. Ozawa, 2020, BMJ Open.

Histologic transformation of epidermal growth factor receptor-mutated lung cancer.

H. Akamatsu, S. Miura, T. Yokoyama, 2022, European journal of cancer.

Immune‐Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non‐Small Cell Lung Cancer

Y. Koh, N. Yamamoto, Y. Ozawa, 2019, The oncologist.

Immune-Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non-Small Cell Lung Cancer.

Y. Koh, N. Yamamoto, Y. Ozawa, 2019, The oncologist.

CD24, not CD47, negatively impacts upon response to PD‐1/L1 inhibitors in non–small‐cell lung cancer with PD‐L1 tumor proportion score < 50

Y. Koh, N. Yamamoto, J. Fukuoka, 2020, Cancer science.

Pre-treatment serum protein levels predict survival of non-small cell lung cancer patients without durable clinical benefit by PD-1/L1 inhibitors

Takanori Yoshikawa, Y. Koh, Y. Ozawa, 2022, Cancer Immunology, Immunotherapy.

Rapid genomic profiling of circulating tumor DNA in non-small cell lung cancer using Oncomine Precision Assay with Genexus™ integrated sequencer

Hiu Ting Chan, M. Nishio, Siew-Kee Low, 2021, Translational lung cancer research.

Second-line immunosuppressant administration for steroid-refractory immune-related adverse events in patients with lung cancer

R. Ariyasu, T. Sonoda, K. Nakatomi, 2023, Cancer Immunology, Immunotherapy.

Mannitol versus furosemide in patients with thoracic malignancies who received cisplatin‐based chemotherapy using short hydration: A randomized phase II trial

H. Akamatsu, A. Hayata, R. Shibaki, 2024, Cancer medicine.